Since 1990, the FTC has challenged at least 20 mergers involving pharma firms. Many of these were resolved through a consent decree and/or the abandonment of the transaction before the FTC filed a suit. In the merger of Pfizer Inc and Pharmacia Corp (2003), it was alleged that the relevant market was R&D and the manufacture and sale of drugs for the treatment of erectile dysfunction, where Pfizer had Viagra among others and Pharmacia had two drugs in the early stages of clinical development. The remedies involved divestiture in nine separate product markets to different third parties. In the merger of Glaxo Wellcome and Smith Kline Beecham (2001), the FTC ordered divestiture in six significant product markets. In addition to the three markets where competitive overlaps existed due to existing agreements with other R&D firms, the consent order addressed competition concerns in several other markets.